Search
for
Sort by
Research 30 of 788
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- Under Development JAK Inhibitors for Dermatologic Diseases
- Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- JAK inhibitors in dermatology: The promise of a new drug class
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Small Molecule Inhibitors and Inflammatory Skin Diseases
- Role of janus kinase inhibitors in the treatment of alopecia areata
- Janus Kinase inhibitors in dermatology: a review
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
- CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1.
- The role of janus kinases in the treatment of autoimmune skin diseases
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- Psychological Stress-Induced Pathogenesis of Alopecia Areata: Autoimmune and Apoptotic Pathways
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches
- Advances in the mechanism and new therapies of alopecia areata
- Peripheral neuropathy associated with tofacitinib use in alopecia universalis
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata
- A novel therapeutic paradigm for patients with extensive alopecia areata
- New drugs under investigation for the treatment of alopecias
- II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata
- A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib
- Comparative analysis of therapeutic outcomes in pediatric versus adult ophiasis-pattern alopecia areata: A review of treatment modalities and disease course
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond